Cynvenio is a cancer diagnostics company focused on transforming cancer treatment through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID™ Breast Cancer molecular testing program and LiquidBiopsy®. ClearID Breast Cancer assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles).